Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

October Declared as Contact Lens Safety Month by Prevent Blindness to Provide Public with Information on How to Keep Eyes Healthy


Prevent Blindness declares October as Contact Lens Safety Month to educate consumers on ways to keep eyes healthy while using contact lenses.

“It’s important to follow the advice of an eye care professional to avoid painful and potentially blinding eye infections from improper or unsafe practices,” said Jeff Todd, president and CEO of Prevent Blindness.

Because an estimated 45 million people in the United States wear contact lenses, according to the U.S. Food and Drug Administration, Prevent Blindness, the nation’s oldest volunteer non-profit eye health organization, has declared October as Contact Lens Safety Month. Contact lenses are classified as medical devices and it is important for consumers to use them safely and under the direction of an eye care professional. Prevent Blindness seeks to provide the public with information to keep eyes healthy while using contact lenses.

The FDA states that contact lenses are not over-the-counter (OTC) devices. Companies that sell them as such are misbranding the device and violating Federal Trade Commission regulations by selling contact lenses without a prescription. Contact lenses sold without a prescription from unlicensed vendors such as certain online distributors, novelty stores or tattoo parlors may be contaminated and/or counterfeit and therefore not safe to use.

According to the American Academy of Ophthalmology, there are a number of things that can cause a contact lens-related infection. Some causes of infection may include:

  • using extended-wear lenses
  • sleeping in your contact lenses
  • having microbes build up under the lens
  • herpes virus
  • bacteria, fungi, or parasites
  • not keeping lenses or cases clean, or reusing or topping off contact lens solution

Additionally, the Centers for Disease Control and Prevention (CDC) has stated that there is no evidence to suggest contact lens wearers are more at risk for acquiring COVID-19 than eyeglass wearers. Nevertheless, contact lens wearers should continue to practice safe contact lens wear and care hygiene habits.

Wearing contact lenses, especially sleeping in the lenses, increases the risk of both infectious and noninfectious keratitis. Keratitis, also known as “corneal ulcer,” is an inflammation of the cornea – the clear, dome-shaped window located at the front of the eye that covers the iris and pupil.

Symptoms of keratitis include:

  • Eye pain and/or eye redness
  • Excess tears or other discharge from your eye
  • Difficulty opening your eyelid because of pain or irritation
  • Blurred vision
  • Decreased vision
  • Sensitivity to light (also called photophobia)
  • A feeling that something is in your eye

Keratitis can cause permanent vision loss. Seek medical attention from an eye doctor right away if any of these symptoms are present. For more information on keratitis, visit the new Prevent Blindness online resource at: https://preventblindness.org/keratitis/. The development of this new resource was supported by a grant from Mallinckrodt Pharmaceuticals.

“Contact lenses can be a good alternative to eyeglasses for many people,” said Jeff Todd, president and CEO of Prevent Blindness. “It’s important to follow the advice of an eye care professional to avoid painful and potentially blinding eye infections from improper or unsafe practices.”

For more information on contact lens safety, please visit http://www.preventblindness.org/wearing-contact-lenses. For more information on keratitis, please visit https://preventblindness.org/keratitis/.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, or to make a contribution to the sight-saving fund, call 1-800-331-2020. Or, visit us on the Web at preventblindness.org or facebook.com/preventblindness.

Share article on social media or email:

Advantages of Oncolytic Viruses as Immunotherapies to be Discussed by Catalent Gene Therapy Expert at World Vaccine Congress


Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that George Buchman, Ph.D., Vice President, Preclinical & Process Development, Catalent Cell & Gene Therapy, will present at the World Vaccine Congress, which will take place virtually on Sept. 28 – October 1, 2020.

On Sept. 30 at 4:05 p.m. EST, Dr. Buchman will present “Next-Generation Vaccines and Oncolytic Viruses: Current Challenges and Future Promise”, giving an overview of the benefits and limitations of oncolytic viruses as immunotherapies. His presentation will discuss the manufacturing and analytical considerations, as well as a collaborative study that evaluates a new technology to assess transfection efficiency.

Dr. Buchman joined Catalent through its acquisition of Paragon Gene Therapy in 2019. He has more than 30 years of experience in the biotech industry, and has held roles at companies including Life Technologies (now Thermo Fisher), Celera Genomics and Gene Logic. Dr. Buchman obtained a bachelor’s degree in biochemistry from Albright College, Reading, Pennsylvania, and a doctorate in biochemistry from University of Maryland.

For more information, please visit https://biologics.catalent.com/events/world-vaccine-congress/.

About Catalent Cell & Gene Therapy

With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com/cell-gene-therapy/

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

New Study by ABSTRAX & University of California, Riverside Sheds Light on Vaping Byproducts


News Image

TEC Temper vs. Other Terpene Diluents

First peer reviewed study on dangerous byproducts created during vaping of certain liquid diluents and their potential role in…illnesses and several deaths.

ABSTRAX, an industry leader in the study and production of cannabis and botanically-derived terpenes, and the University of California, Riverside (UCR) have officially released their first peer reviewed study on dangerous byproducts created during vaping of certain liquid diluents and their potential role in more than 2800 vape-related illnesses and several deaths.

The initial study, directed by Dr. Huanhuan Jiang from the Lin Lab at UCR and T.J. Martin, Director of Research and Development at ABSTRAX, concluded that vitamin E (VE) and vitamin E acetate (VEA) may not only contribute to E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI), but both ingredients also form toxic byproducts.

“We found these byproducts work to form oxygenated radical degradants that are very harmful, so not only does VE and VEA possibly lead to EVALI via lipid lung disease, but they also form byproducts that are extremely dangerous,” says Martin.

To reach this conclusion, ABSTRAX and UCR scientists collaborated to understand how commonly used vape juice diluents — including vitamin E (VE), vitamin E acetate (VEA), propylene glycol (PG), triethyl citrate (TEC), vegetable glycerin (VG), squalane oil (SQL) and coconut oil or medium-chain triglyceride (MCT) oil — react to the high temperatures produced during the vaping process.

“Some of these liquid diluents and viscosity enhancers are generally considered safe additives for food via ingestion. However, their safety has not been fully assessed for vaping inhalation, a process that can potentially degrade the liquid ingredients and produce reactive and toxic compounds such as formaldehyde, acetaldehyde, and acrolein that are known human carcinogens,” says Martin.

To best understand how the above diluents react to heat, ABSTRAX and UCR worked to answer the following questions:

     a. Do the diluents degrade under normal vape temperatures, and if so, what are the byproducts they degrade into?

     b. Do the byproducts have a significant impact on cellular toxicity?

     c. Are there different cellular responses for different diluents and their byproducts?

The initial findings of the study show that all of the aforementioned diluents thermally transform to some extent when vaped, and some byproducts may be toxic if consumed at high enough concentrations. A follow up study will quantify these products and confirm the extent of toxicity.

Additionally, some diluents produced significantly less byproducts than others, but were far more dangerous than most that formed several byproducts. For example, VE and VEA were two of three diluents that formed the lowest number of byproducts during vape scenarios, but the two byproducts formed by VE and VEA (duroquinone and durohydroquinone) are particularly worrisome.

These VE and VEA byproducts can form radical oxidation compounds that are very damaging to lung cells. What was even more a cause of concern for the scientists is that the two byproducts have already been studied for decades in relation to toxic air pollution.

“While our research uncovered important information about the chemistry of vaping these diluents, it must be mentioned that we do not know the concentrations formed during a normal ‘smoke session,’” says Martin. “We ran all tests in a laboratory setting using instruments in a controlled environment and obtained human bronchial epithelial cells that were then exposed to both unvaped liquid diluents and vaping emission samples for 48 hours. The next step in this work is to more closely emulate the vaping conditions a general consumer would experience to determine what amount of these degradation compounds are present.”

The researchers also don’t have the full story as to which diluent is the safest; however, this body of research is the first piece of the puzzle in understanding how the byproducts may affect users.

What the researchers did discover was that every diluent, except TEC, showed significant changes in cellular toxicity after vaping. TEC was the only diluent that did not have a significant difference between vaped and unvaped exposure. Although the unvaped TEC showed some toxicity at the highest measured concentrations, when vaped, it did not increase in toxicity, potentially indicating that the byproducts were not as harmful as the other diluent vape products. These findings will be further quantified in a follow up study.

In addition, studies using lactate dehydrogenase assays (LDH) were conducted to determine if the vape degradants induced damage to cell membranes. These results revealed that exposure to MCT, Squalane, and VE increased LDH release — indicating that the vaping products of these compounds are disrupting cell membranes at highly concentrated levels (significantly above that of a normal vape consumption) — whereas TEC did not have a significant increase. Further studies are needed to fully understand the implication of these results.

The following summarizes the number of degradants observed along with their general chemical functionality:

     a. PG – primarily formed reactive carbonyls – 6 degradants

     b. VG – primarily formed reactive carbonyls – 7 degradants

     c. Vitamin E – formed highly reactive organic compound durohydroquinone – 4 degradants

     d. Vitamin E Acetate – formed highly reactive organic compounds duroquinone and durohydroquinone – 6 degradants

     e. Squalane – produced alkanes and reactive carbonyls – 13 degradants

     f. Triethyl Citrate – primarily short chain esters – 4 degradants

     g. MCT Oil – many types of compounds including short chain esters, alkanes, reactive carbonyls (e.g. formaldehyde),

         and alkyl alcohols (e.g. tridecanol) – 19 degradants

The sheer number of degradants in the diluents can be alarming, but researchers do not know the concentrations during normal vaping conditions. It is important to note that the amount of degradants is not as important as the identity and the toxicity of the degredent compounds. For example, squalane has 13 degradents that are not glaringly dangerous, whereas Vitamin E has four degradents, but they are known toxins that are far more dangerous and cause physical harm.

Taken together, these results shed light on the complex chemistry that occurs during vaping and their possible effects on human lung cells. The identification of the degradation byproducts combined with the cell studies are a first step in understanding the safety of these diluents. However, additional studies that more closely emulate the vaping experience are needed to determine the amount of each produced, and if those levels have significant health effects.

About ABSTRAX

Leveraging its proven background in cannabis research, ABSTRAX is the leader in the research, development, and production of botanically-derived and cannabis-inspired terpenes that create unforgettable sensorial experiences. Headquartered in California, the company owns and operates a state-of-the-art type 7 licensed research and manufacturing lab where it’s award-winning product developers and scientists leverage the most advanced strain analysis technology to extract and study aroma compounds via three-dimensional analysis, allowing for each and every compound within a plant to be named and studied. The company has partnered with many of the best cultivators in the industry to study their cannabis profiles and create the world’s most advanced terpene formulations. As a result of its efforts, ABSTRAX offers the largest terpene catalogue of the most popular strains – botanically-derived terpene blends and isolates native to cannabis. These ingredients, also known as functional flavors and aromas, are used in vapes, concentrates, edibles, beer, essential oils, fragrances, cosmetics, topicals, tinctures, alcohol, food and beverage, personal care, and more. The company works with internationally recognized brands and provides unparalleled cannabis research, innovation, and custom formulations to create products that engage and thrill consumers. ABSTRAX also devotes significant resources to developing the highest terpene standards and best practices in the industry. The company has developed a robust quality management system including Gas Chromatography analysis and molecular distillation of natural ingredients to achieve the highest purity standards. Investigating and ensuring that ingredients used in its own products, and products within its industry, are safe for consumption. The terpene industry is a rapidly growing segment of the global flavor and fragrance market, which is expected to grow to $35 billion by 2024. This market segment includes the cannabis, CBD, skincare, cosmetics, health and wellness, food and beverage industries. For more information, visit AbstraxTech.com.

Improve Drug Project Success by Understanding Drug Target Safety, Upcoming Webinar Hosted by Xtalks


Xtalks Logo

Xtalks Life Science Webinars

Experts will describe how we derive relevant insights from the vast amount of publicly available information to provide clients with a focused assessment of key risks, tailored for each individual project.

At least 50 percent of drug safety failures are attributable to target-related effects. So, it makes sense to understand potential safety liabilities associated with a target early in projects, in order to anticipate and manage those issues before they arise.

A target safety assessment (TSA) brings together public domain information (target homology, gene and protein expression profiles, transgenic and mutation phenotype data, competitor compounds) into a report that identifies and categorizes key risks by organ/tissue and by physiological functions. This systematic categorization is used as the basis of a risk mitigation plan with ranking of risks and potential next steps, presented as a Word document with embedded PowerPoint.

Join this educational webinar to learn how target safety assessments (TSAs) are used to determine the potential consequences of modulating a target and provide options on how to assess those risks. Experts will describe how we derive relevant insights from the vast amount of publicly available information to provide clients with a focused assessment of key risks, tailored for each individual project.

Join Professor Ruth Roberts, Director and Co-founder, ApconiX Ltd, Dr. Claire Sadler, Project Toxicologist, ApconiX and Dr. Leigh Ann Burns Nass, President/Owner, Magnolia Toxicology Consulting, LLC in a live webinar on Thursday, October 1, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Improve Drug Project Success by Understanding Drug Target Safety.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

RADLogics Announces FDA Clearance and Validation for AI-Powered Application to Support Chest X-ray Triage and Prioritization


RADLogics

We are very pleased to receive FDA 510(k) clearance for our AI-Powered chest X-ray pneumothorax application, which adds to our array of AI-Powered solutions for CT and X-ray that are designed to improve efficiency and reduce burnout for radiologists that are under greater pressure than ever before.

– RADLogics is deploying the company’s X-ray and CT solutions to hospitals in accordance with FDA guidance for imaging systems and software to address the COVID-19 public health emergency

  • Company highlights validation of solution via preprint of new paper entitled “COVID-19 in CXR: from Detection and Severity Scoring to Patient Disease Monitoring”

RADLogics™ today announced that the company’s novel AI-Powered chest X-ray pneumothorax application has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance paves the way for healthcare providers, hospital networks and clinicians to have access to artificial intelligence (AI) software that is trained via pattern recognition to process chest X-rays and immediately flag scans with a suspected pneumothorax, a collapsed lung, for urgent radiologist review. The application is available immediately through the Nuance AI Marketplace for Diagnostic Imaging.

Operating in parallel with existing workflow, RADLogics’ chest X-ray solution uses an artificial intelligence algorithm to analyze images for features suggestive of pneumothorax. It then makes case-level output available to a PACS workstation for worklist prioritization or triage. The AI-Powered solution integrates into a comprehensive, seamless, and secure workflow to augment acute care teams with deep clinical insight and actionable data in minutes. The application was validated and trained by a multi-center study for detecting pneumothorax in hundreds of chest X-rays.

“We are very pleased to receive FDA 510(k) clearance for our AI-Powered chest X-ray pneumothorax application, which adds to our array of AI-Powered solutions for CT and X-ray that are designed to improve efficiency and reduce burnout for radiologists that are under greater pressure than ever before,” said Moshe Becker, CEO and Co-Founder of RADLogics. “From extreme pressure on capacity and resources to a major financial strain due to the ongoing COVID-19 pandemic, there is no question that the healthcare system is in need for new solutions such as AI to augment caregivers to alleviate the increased burden and support better outcomes.”

In accordance with FDA guidance for imaging systems and software to address the COVID-19 public health emergency, RADLogics has made its FDA cleared X-ray and CT solutions available to hospitals and healthcare systems throughout the U.S. for patient triage and management. Designed for easy integration and installation both on-premise and via the cloud – RADLogics’ algorithms are supported by the company’s patented workflow software platform that enables rapid deployment at multiple hospitals, and seamless integration with existing workflows.

To further validate the use of chest X-ray solutions, the company highlighted a new paper in preprint entitled “COVID-19 in CXR: from Detection and Severity Scoring to Patient Disease Monitoring”. Led by Professor Hayit Greenspan from Tel Aviv University and members of the RADLogics’ algorithm development team, the paper studied the severity of pneumonia in COVID-19 patients through a longitudinal study of disease progression. Using a deep learning model for simultaneous detection and segmentation of pneumonia in chest X-ray (CXR) images and generalized to COVID-19 pneumonia, the study found that the measurement of disease severity through a “Pneumonia Ratio” that enabled the research team to build a disease extend profile over time for hospitalized patients.

Results of this study are available on arXiv.org, and it has been submitted to the JBHI IEEE journal for review and potential publication.

About RADLogics

RADLogics is a healthcare software company developing AI-Powered solutions that support image analysis to improve radiologists’ productivity while enhancing patient outcomes. Based in Boston, MA, U.S., and Tel Aviv, Israel, RADLogics is one of the pioneers in using AI & machine learning image analysis and advanced big data analytics to search and analyze imaging data from CTs, MRIs, PET scans, and X-rays to help reduce diagnostics turnaround time from hours to minutes by automating detection and report generation functions. The company’s patented AI medical image analysis platform enables rapid development of AI algorithms, and provides seamless integration into existing radiology workflow. Visit http://www.radlogics.com to learn more or follow us on LinkedIn or Twitter.

Share article on social media or email:



The 3PL of the Future—Value Added Disruption in Logistics, Upcoming Webinar Hosted by Xtalks


Xtalks Logo

Xtalks Life Science Webinars

Third-party providers are working smarter through technologically enabled solutions to find efficient capacity, discover accurate pricing, and eliminate many roadblocks that slowed down predecessors.

When most picture the logistics industry or 3PL of the future, they think of automated self-driving vehicles or package delivering drones. While these may be in-store someday, these lofty advancements currently remain more aspirational than tangible. Despite being a long way off from a complete infrastructure overhaul, transformation is still happening at 3PL firms every day.

In this webinar, Zipline Logistics’ president and co-founder, Andrew Lynch, will discuss the 3PL and logistics industry of the future by highlighting the technological advancements currently in the space and how firms are incorporating those to find performance-enhancing and cost-reducing retail delivery strategies.

The discussion will focus on how strides in productivity, connectivity, and visibility tools have transformed 3PLs and helped increase the efficiency of the CPG supply chain.

From real-time tracking to price-matching technology, today’s 3PL is much different from the one of decades past. Third-party providers are working smarter through technologically enabled solutions to find efficient capacity, discover accurate pricing, and eliminate many roadblocks that slowed down predecessors.

This webinar aims to give CPG brands a look into the tools that are being used to deliver their freight to retail customers in an efficient and cost-effective manner. Learn how 3PL specialization, service, and technological insights, are paving the way for a brighter logistics future.

Join Andrew Lynch, President and Co-Founder of Zipline Logistics in a live webinar on Friday, October 2, 2020 at 1pm EDT (6pm BST/UK).

For more information or to register for this event, visit The 3PL of the Future—Value Added Disruption in Logistics.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

U.S. Food and Drug Administration Selects Cambridge Semantics for Data and Analytics Platform


Cambridge Semantics, the leading provider of modern, graph-driven data integration for the enterprise data fabric, today announced that the U.S. Food and Drug Administration (FDA) has selected Cambridge Semantics as the analytics and integration layer for the FDA’s Intelligent Data Lake.    

The FDA’s Center for Drug Evaluation and Research (CDER) has begun a new strategic initiative to enhance its enterprise data architecture and regulatory review. The Intelligent Data Lake, when complete, will provide a platform for integrating data for analytics and insights pertaining to new drug applications, generic formulations, risk evaluation, translational science, and pharmaceutical quality.

“Cambridge Semantics’ Anzo enhances the data lake with the critical capability to rapidly blend and analyze data in support of multiple, diverse use cases,” said a senior program leader at the FDA.    

“We are excited and proud to be chosen as the data integration platform to accelerate the FDA’s digital strategy,” said Chuck Pieper, Chairman, and CEO of Cambridge Semantics. “Our graph technology uniquely enables the speed and scale required to integrate data for large, distributed organizations like the FDA.”

Cambridge Semantics’ Anzo provides a modern, graph-driven data integration platform to connect and bring meaning to all enterprise data and enable virtually anyone in an organization – from skilled data scientists to novice business users – to develop analytics-ready data sets that combine any data from any system across the enterprise. Anzo drives digital transformation and enables deep business insights when an organization’s data is highly distributed, vastly siloed, complex, and when users want answers to unanticipated questions at speed and scale.

“A principal advantage of Anzo over alternative solutions is that the FDA and their trusted consulting partners now model, integrate and visualize the data in a self-service manner,” said Ben Szekely, Senior Vice President of Field Operations at Cambridge Semantics. “We have provided an efficient, focused field team to enable the FDA to execute many high-value use cases in a rapid, scalable, cost-effective manner. The FDA will also enjoy the flexibility of applying their trusted BI and analytics tools to the integrated data sets in Anzo.”

About Cambridge Semantics

Cambridge Semantics Inc is a modern, graph-driven data integration and analytics software company that enables seamless access to all enterprise data. Cambridge Semantics was recently recognized as a leader in Forrester Research’s Enterprise Data Fabric Wave.

The company delivers products and solutions that enable IT departments and business users across Life Sciences, Healthcare, Financial Services, Government, Manufacturing, and other industries to accelerate data delivery and to provide meaningful insights across the organization at speed and scale.

Cambridge Semantics is based in Boston, Massachusetts.

For more information visit http://www.cambridgesemantics.com or follow us on Facebook, LinkedIn, and Twitter: @CamSemantics.

About FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Share article on social media or email:

Icahn School of Medicine at Mount Sinai Unveils BioMedical Laureates Program to Drive Diversity, Enhance Mentorship


“This program is among the first programs of its kind in the country that is dedicated to the enhancement of diversity among senior research scientists at an academic medical center. “

The Icahn School of Medicine at Mount Sinai today unveiled BioMedical Laureates at Mount Sinai, a program intended to increase diversity among its basic and clinical research faculty and reinforce the school’s strong ethic of mentorship. BioMedical Laureates and a companion program, Junior Laureates, will both launch in January, 2021, and will each announce new Laureates annually.

“This program is among the first programs of its kind in the country that is dedicated to the enhancement of diversity among senior research scientists at an academic medical center. The program will significantly add to our existing efforts to diversify our faculty,” says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System. “A diverse medical and scientific community will drive innovation, enhance clinical care, and enrich teaching and mentorship, fulfilling the mission that drives our work. Our Laureates will bring with them a breadth of ideas and lived experiences, while lending new perspectives and raising new questions, which in turn will lead to lasting systemic change.”

The program will include two components: a biomedical laureates program and a complementary junior program. The Mount Sinai BioMedical Laureate will be selected based on the candidate’s scientific track record and future promise as a leader in academic medicine, and will undergo rigorous review by a committee of senior researchers from across the institution. Selected Laureates will be given a competitive startup package based on scientific and professional development needs, which includes five years of salary, support. Two BioMedical Laureates will be selected each year, one in basic science, the other in translational or clinical science.

The Junior Laureate Program seeks candidates who have completed their doctoral degree. Junior Laureates will have the opportunity to develop their own independent research program as a member of an existing research team. Upon completion of research milestones, the Junior Laureate will transition to a Mount Sinai BioMedical Laureate position and benefits package. Two Junior Laureates will be selected each year, again one in basic science, the other in translational or clinical science.

“Having experienced first-hand the barriers and challenges associated with establishing a career in science as a Black or Latina scientist, I am really delighted that Mount Sinai is putting forth this effort and investing in what is truly the future of our research workforce,” says Lynne D. Richardson, MD, Professor of Emergency Medicine and of Population Health Science and Policy, System Vice Chair of Emergency Medicine, and Co-Director of the Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai.

In partnership with the Mount Sinai Office for Diversity and Inclusion and the Center for Multicultural and Community Affairs, Laureates will be mentored and guided by an advisory group of diverse leaders in science and medicine. Mentorship will form the bedrock of each program.

“Mount Sinai Laureates will be given extensive professional training and guidance as they navigate a career in academic medicine,” says Eric J. Nestler, MD, PhD, Nash Family Professor of Neuroscience, Director of The Friedman Brain Institute, and Dean for Academic and Scientific Affairs. “We will do everything we can to ensure that our Laureates thrive and their research flourishes. In five years, these programs will add 20 Black and Latinx scientists to our faculty, fundamentally changing the basic and clinical research landscape at Mount Sinai. Diversity, inclusion, and equity represent the means of achieving our mission to advance biomedicine and provide compassionate and equitable care in service to our community.”

Candidates interested in more information should please contact Eric J. Nestler, MD, PhD, at eric.nestler@mssm.edu.

###

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

Zesty Paws® Debuts New Lil’ Zesties Square Chews


News Image

Zesty Paws®, a leading functional pet supplements brand, has launched a new product for pet parents looking to help their dogs live their zestiest life with Zesty Paws® Lil’ Zesties Squares™.

Zesty Paws®, a leading functional pet supplements brand, has launched a new product for pet parents looking to help their dogs live their zestiest life with Zesty Paws® Lil’ Zesties Squares™. The flat square-shaped functional chews provide support for various functions and come in Smoked Turkey flavor and four functional areas: Aller-Immune, Calming, Probiotic and Mobility.

“Through our proprietary approach, we’re pleased to bring to market a product that will help support key functional areas in dogs while also being a mouth-watering, smokey dog chews in a new flat square format,” said Steve Ball, CEO of Zesty Paws®. “We know these delicious functional chews live up to our promise to help you ‘Keep Your Bestie Feeling Zesty™.’”

Zesty Paws® Lil’ Zesties Aller-Immune Squares™ may help seasonal allergy symptoms in dogs and support the immune system’s response. Made with a blend of Turmeric, Licorice Root, and EpiCor®, these chews support and enhance the immune system and may help maintain normal histamine levels.

Zesty Paws® Lil’ Zesties Calming Squares™ may help reduce the effects of normal environmental stress in dogs and may promote calming effects in dogs exhibiting nervousness, hyperactivity, discontentment or responding to environmentally induced stress like storms or fireworks. Made with premium ingredients like Chamomile, Passionflower and Melatonin, these chews also help to maintain contentment during separation, travel, motion sickness and tension caused by changes in the pet’s daily routine.

Zesty Paws® Lil’ Zesties Probiotic Squares ™ helps maintain a healthy intestinal tract and proper gut flora to promote normal bowel function. Made with Ginger and GanedenBC30®, which helps promote healthy digestion and support a healthy immune system, these Squares are a good choice to maintain a healthy gut.

Zesty Paws® Lil’ Zesties Mobility Squares™ helps ease joint stiffness associated with normal daily exercise. These bites feature Glucosamine HCl, Chondroitin Sulfate, and MSM to help support joints, maintain healthy cartilage and connective tissue, and support hip and joint function.

Zesty Paws Lil’ Zesties Squares™ products are now available online on Amazon, Chewy and ZestyPaws.com.

Zesty Paws® is the leading brand for top rated pet functional supplements, with products crafted to support key functional areas for cats and dogs in different stages of their lives, regarding Gut Health, Immunity, Grooming, Behavior and more. With delicious flavors and functional premium ingredients, Zesty Paws soft bites are the perfect way to Keep Your Bestie Feeling Zestie™.

Learn more about Zesty Paws® at ZestyPaws.com or by following the brand on Instagram.

About Zesty Paws®

Since 2014, Zesty Paws® is lead by a team of pet parents who have been committed to providing premium products to enable and inspire a ZEST FOR LIFE in pets and pet parents. As a top rated pet functional supplement brand, Zesty Paws® is the most trusted brand for innovative solutions that guide and empower the journey to wellness. Specializing in dog and cat care, Zesty Paws® products Keep Your Bestie Feeling Zesty™. For more information visit https://zestypaws.com/.

Share article on social media or email:

DeCurtis Corporation Partners with SMS International Shore Operations to Improve the Health in Ports Worldwide


News Image

“SMS International Shore Operations is excited to partner with DeCurtis as they both work for safe and successful resumption of cruise operations., “said Samuel Mifsud, Managing Director, SMS International Shore Operations.

DeCurtis Corporation, the premier provider of location and proximity enabled solutions in complex, indoor environments with a focus on health, safety and security, operational enhancement and experience evolution announces a partnership with SMS International Shore Operations, the world’s leader in managing port experiences and operations for cruise liners globally.

SMS will operate DeCurtis Shield™ Kiosks to automate the health check questionnaire process and provide temperature screening as part of its new health and safety initiative due to COVID-19.    

“SMS International Shore Operations is excited to partner with DeCurtis as they both work for safe and successful resumption of cruise operations,” said Samuel Mifsud, Managing Director, SMS International Shore Operations. “Our collective strengths and combined industry knowledge will bring real value to our mutual clients when they are preparing for the re-start of operations. We are pleased to collectively introduce an ultimate turn-key solution by combining the cutting-edge technology with dedicated, experienced, and service-oriented staff to run it. We are confident it will allow existing and future clients to be a step ahead of resuming safe cruise operations.”

This partnership aims to seamlessly enhance the health, safety and security at ports worldwide while continuing to deliver value to the cruise lines and guests both companies serve using DeCurtis Shield™. Health, safety and security have always been vital components of DeCurtis Corporation’s mission but are the primary focus in the cruise industry’s current environment. DeCurtis Shield ™ focuses on improving indoor environments using patent-pending technology to quickly implement health screenings at any secure entry or exit point. This technology is not just an answer to COVID-19, but a critical part of a mitigating strategy to lessen onboard outbreaks.    

“SMS and DeCurtis have both built strong relationships with the cruise industry, so the partnership is a great fit,” said Camille Olivere, Senior Vice President Sales and Marketing, DeCurtis Corporation. “DeCurtis understands that the biggest challenge to implementing new technology is to put it into operations. SMS provides a seamless way to implement DeCurtis Shield health screening technology in the embarkation and disembarkation process. The great service that SMS provides will become more efficient and improve peace of mind as well as the health and safety of SMS employees and cruise guests.”

About SMS International Shore Operations

SMS is an industry leader that has been providing all passenger logistics services including port agency, turnaround services, and shore excursions worldwide for well over 20 years. Our teams welcome cruise guests from around the world and accommodate the needs of thousands of cruise ships annually. SMS has a long history, founded in 1950, “SMS Shipping” has grown globally with a proven track record of providing outstanding service and a reputation for professionalism. SMS and its local support teams have worked aggressively through our partnerships with over 20 cruise lines and over 30 global locations, where we aim to exceed our client and guest expectations every day. http://smscruises.com http://www.sms.com.mt

About DeCurtis Corporation   

DeCurtis Corporation is the premier provider of location and proximity enabled solutions in complex indoor environments with a focus on health, safety and security, operational enhancement and experience evolution. Creator of Mobile Assembly Suite (MAS™), the DeCurtis Experience Platform (DXP™), and DeCurtis Shield™, DeCurtis Corporation is the leader in providing transformational experience technology based on decades of deep industry knowledge in the cruise space that is applicable to other sectors. With a vast range of experience working with some of the world’s best, most-recognized brands, DeCurtis Corporation transforms the guest experience to be safer, secure and more efficient through the creative application of the latest technology. For more information on DeCurtis Corporation, please visit http://www.decurtis.com.

Share article on social media or email: